A Randomized Trial of Raltegravir Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor in HIV-Infected Women with Lipohypertrophy

被引:24
|
作者
Lake, Jordan E. [1 ]
McComsey, Grace A. [2 ]
Hulgan, Todd M. [3 ]
Wanke, Christine A. [4 ]
Mangili, Alexandra [4 ]
Walmsley, Sharon L. [5 ]
Boger, M. Sean [6 ]
Turner, Ralph R. [7 ]
McCreath, Heather E. [1 ]
Currier, Judith S. [1 ]
机构
[1] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA
[2] Case Western Reserve Univ, Dept Pediat & Med, Cleveland, OH 44106 USA
[3] Vanderbilt Univ, Dept Med, Nashville, TN USA
[4] Tufts Univ, Dept Med, Boston, MA 02111 USA
[5] Univ Toronto, Dept Med, Toronto, ON, Canada
[6] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA
[7] Phase V Technol Inc, Wellesley, MA USA
基金
美国国家卫生研究院;
关键词
REGIONAL ADIPOSE-TISSUE; ANTIRETROVIRAL THERAPY; INTRAABDOMINAL FAT; GENDER-DIFFERENCES; LIPOPROTEIN LEVELS; LIPODYSTROPHY; PREVALENCE; EFAVIRENZ; REGIMENS; LIPOATROPHY;
D O I
10.1089/apc.2012.0135
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Lipohypertrophy in HIV-infected patients is associated with metabolic abnormalities. Raltegravir (RAL) is not known to induce fat changes or severe metabolic perturbations. HIV-infected women with central adiposity and HIV-1 RNA less than 50 copies per milliliter on non-nucleoside reverse transcriptase inhibitor (NNRTI)- or protease inhibitor (PI)-based antiretroviral therapy (ART) continued their nucleoside reverse transcriptase inhibitor (NRTI) backbone and were randomized to switch to open label RAL immediately or after 24 weeks. The primary end point was 24-week between-group change in computed tomography (CT)-quantified visceral adipose tissue (AT) volume. Fasting lipids, glucose, C-reactive protein (CRP), anthropometric measurements, and patient-reported quality of life assessments were also measured. Thirty-six subjects provided 80% power to detect a 10% between-group difference in visceral AT over 24 weeks. Thirty-seven of 39 enrolled subjects completed week 24. At entry, subjects were 75% black or Hispanic, and on 62% PI-based and 38% NNRTI-based regimens. The median age was 43 years, CD4 count 558 cells per microliter, and body mass index (BMI) 32 kg/m(2). After 24 weeks, no statistically significant changes in visceral or subcutaneous AT, anthropometrics, BMI, glucose, or CRP were observed. In subjects receiving RAL, significant improvements in total and LDL cholesterol (p = 0.04), self-reported belly size (p = 0.02) and composite body size (p = 0.02) were observed. Body size changes correlated well with percent visceral AT change. No RAL-related adverse events occurred. Compared to continued PI or NNRTI, switch to RAL was associated with statistically significant 24-week improvements in total and LDL cholesterol but not AT volumes. Additional insights into AT and metabolic changes in women on RAL will be provided by 48-week follow-up of the immediate-switch arm.
引用
收藏
页码:532 / 540
页数:9
相关论文
共 50 条
  • [31] Synthesis of Some Novel Non-Nucleoside Reverse Transcriptase Inhibitor
    Bapna, Mayank
    Nema, R. K.
    [J]. ASIAN JOURNAL OF CHEMISTRY, 2009, 21 (02) : 1244 - 1248
  • [32] Nucleoside-reverse-transcriptase inhibitor associated mitochondrial toxicity in exposed HIV-infected pregnant women
    Kost, B.
    Sovric, M.
    Kaestner, R.
    Mylonas, I
    Friese, K.
    Gingelmaier, A.
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2009, 69 (05) : 448 - 448
  • [33] Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor
    Freimuth, WW
    [J]. ANTIVIRAL CHEMOTHERAPY 4: NEW DIRECTIONS FOR CLINICAL APPLICATION AND RESEARCH, 1996, 394 : 279 - 289
  • [34] Reversal of Growth Failure in HIV-Infected Thai Children Treated with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy
    Aurpibul, Linda
    Puthanakit, Thanyawee
    Taecharoenkul, Sineenart
    Sirisanthana, Thira
    Sirisanthana, Virat
    [J]. AIDS PATIENT CARE AND STDS, 2009, 23 (12) : 1067 - 1071
  • [35] Integrative approaches in HIV-1 non-nucleoside reverse transcriptase inhibitor design
    Poongavanam, Vasanthanathan
    Namasivayam, Vigneshwaran
    Vanangamudi, Murugesan
    Al Shamaileh, Hadi
    Veedu, Rakesh N.
    Kihlberg, Jan
    Murugan, N. Arul
    [J]. WILEY INTERDISCIPLINARY REVIEWS-COMPUTATIONAL MOLECULAR SCIENCE, 2018, 8 (01)
  • [36] Etravirine: A unique non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1
    Girotto, Jennifer E.
    [J]. FORMULARY, 2010, 45 (03) : 78 - +
  • [37] Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice
    Molto, Jose
    Blanco, Asuncion
    Miranda, Cristina
    Miranda, Jose
    Puig, Jordi
    Valle, Marta
    DelaVarga, Meritxell
    Fumaz, Carmina R.
    Barbanoj, Manuel Jose
    Clotet, Bonaventura
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (06) : 715 - 721
  • [38] Increased carotid intima-media thickness in HIV-infected patients exposed to protease inhibitor-compared to non-nucleoside reverse transcriptase inhibitor-containing combination antiretroviral therapy
    Sankatsing, Raaj R.
    Wit, Ferdinand W.
    Vogel, Martin
    de Groot, Eric
    Brinkman, Kees
    Rockstroh, Juergen K.
    Kastelein, John J.
    Stroes, Erik S.
    Reiss, Peter
    [J]. CIRCULATION, 2007, 116 (16) : 461 - 461
  • [39] Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs
    Moore, RD
    Keruly, JC
    Chaisson, RE
    [J]. AIDS, 2001, 15 (05) : 617 - 620
  • [40] Lack of Effect of Doxycycline on Trough Concentrations of Protease Inhibitors or Non-Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients
    Abgrall, S.
    Le Bel, J.
    Lele, N.
    Laouenan, C.
    Eychenne, N.
    Mentre, F.
    Peytavin, G.
    Bouchaud, O.
    [J]. HIV CLINICAL TRIALS, 2013, 14 (06): : 313 - 318